louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06868524: Leading Healthy Eating and Activity Promotion Program
Official title: Leveraging Adaptation and Multilevel Implementation Strategies to Address Unique Health Promotion Challenges Among Cancer Survivors
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Cancer Survivor
Cancer
Oncology
Keywords: cancer survivor
cancer
oncology
exercise
nutrition
diet
healthy lifestyle
behavior change
Lead sponsor: University of Alabama at Birmingham
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2025-03-11
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 89
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: cancer survivors or the friend/family member of a cancer survivor

Brief summary: The goal of the LEAP project is to improve the health and well-being of cancer survivors and their co-survivors living in persistent poverty areas by providing healthy behavior change support. This will be done by engaging the community in adapting beneficial approaches for promoting healthy diet and regular physical activity into a program for cancer survivors and co-survivors that is appropriate for the persistent poverty context and social determinants of health.


Eligibility criteria: Inclusion Criteria:

* Between the ages of 18 and 89
* English speaking
* Resident of Birmingham area or surrounding community
* History of any type of cancer or the friend or family with of a cancer survivor

Exclusion Criteria:

* Serious difficulty hearing
* History of dementia or organic brain syndrome
* On primary treatment for cancer
* No other other medical, psychological, or social characteristic that would interfere with participation in evaluation

Primary outcomes:
measure: Number of participants that meet the dietary guidelines for healthy diet
timeFrame: Baseline, 12-weeks
measure: Number of participants that meet the recommended minutes of physical activity per week
timeFrame: Baseline, 12-weeks
measure: Overall quality of life score
timeFrame: Baseline, 12-weeks
measure: Change in BMI
timeFrame: Baseline, 12-weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: University of Alabama at Birmingham
state: Alabama
Study officials:
affiliation: University of Alabama at Birmingham
name: Laura Rogers, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00065624: Antioxidant Functions of Lipoic Acid
Official title: Antioxidant Functions of Lipoic Acid
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Hypercholesterolemia
Keywords: Lipoic acid
F2-isoprostanes
endothelial dysfunction
natural product
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH)
Sponsor class: NIH
First posted: 2003-07-31
Enrollment: 16
Sex: ALL
Minimum age (years): 50
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this study is to determine whether a short treatment with lipoic acid, an antioxidant used in the treatment of diabetic neuropathy, improves blood vessel reactivity and decreases oxidant stress in persons with elevated blood cholesterol.

Detailed description: As per Brief Summary

Eligibility criteria: Inclusion criteria:

* Lipid criteria for inclusion are a plasma LDL between 160 and 190 mg/dl (total cholesterol usually 240-285 mg/dl)
* Less than 2 coronary risk factors, and already on a cholesterol-lowering diet.

Exclusion criteria:

* Overt or clinical atherosclerosis
* Diabetes
* Currently taking cholesterol-lowering medication.
* Subjects with other lipid disorders
* Subjects taking supplemental lipoic acid, vitamin C, or vitamin E.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Nashville
country: United States
facility: Vanderbilt University Medical Center
state: Tennessee
Study officials:
affiliation: Vanderbilt University Medical Center
name: James M May, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06147024: Utilizing 3D Printed Personalized Aortic Lesion Models in Preoperative Assessment
Official title: Utilizing 3D Printed Personalized Aortic Lesion Models to Assist Surgeons in Preoperative Assessment and Planning of Aortic Aneurysm Surgery
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Aortic Aneurysm
Keywords: 3D printing
pre-operative planning
thoracic aorta aneurysm
abdominal aorta aneurysm
Lead sponsor: Fu Jen Catholic University
Sponsor class: OTHER
First posted: 2023-11-27
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Using 3D printing technology to create personalized models of diseased heart and aortic blood vessels, surgeons can perform preoperative planning and evaluate relevant indicators.

Detailed description: Background： Previous systematic reviews have indicated that approximately 82% of surgeries using 3D printed lesion models for preoperative planning have shown better surgical outcomes, and about half of the surgeries have demonstrated reduced operative time. In recent years, there have been numerous studies focusing on the application of 3D printing technology in aortic aneurysms. This study aims to employ 3D printing technology to fabricate personalized aortic blood vessel models with lesions.

Study Design： A single-centre, pilot study.

Methods： This study is a single-center, prospective clinical trial. The study plans to enroll 10 participants in the experimental group, and collect data from another 10 participants as the historical control group. The historical control group data will be matched-paired based on gender, age, and surgical type in sequential order.

Effect： We anticipate that through the use of 3D printed lesion models, we can reduce surgical time, decrease surgery-related complications, and enhance the smoothness of surgical team preparation for the procedure. Additionally, this approach can provide patients with a better understanding of their own condition and the upcoming surgical intervention.

Key words： 3D printing; pre-operative planning; thoracic aorta aneurysm; abdominal aorta aneurysm

Eligibility criteria: Inclusion Criteria:

* Diagnosed with thoracic or abdominal aortic aneurysm
* Signed surgical consent
* Non-emergent surgery
* Had 2D CT imaging within the last 6 months

Exclusion Criteria:

* Refusal to use lesion images for model creation
* Refusal to participate in the study

Primary outcomes:
measure: surgical time
timeFrame: immediately after the surgical procedure
Secondary outcomes:
Other outcomes:
Locations:
city: New Taipei City
country: Taiwan
facility: Fu Jen Catholic University Hospital, Fu Jen Catholic University
Study officials:
affiliation: Fu Jen Catholic University Hospital
name: Ke-Yun Chao, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05578924: Factors Associated With Gynecological Consultation by General Practitioner
Official title: Factors Associated With Gynecological Consultation by General Practitioner
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Adult Daughters
Keywords: Adult women
gynecological acts
general practitioners
Lead sponsor: Université de Reims Champagne-Ardenne
Sponsor class: OTHER
First posted: 2022-10-13
Enrollment: 2000
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: women aged more than 18 years old, who consent to participle to the study

Brief summary: Because of the shortage of doctors in France, notably gynaecologist, general practitioners are definitely an essential partner women's health. However, few of them regularly practice gynecological acts.

A lot of studies have studied why general doctors not practice gynecological acts but it would necessary to include the women's perspective.

Detailed description: The aim of the study will be identify women's factors associated with gynaecological consultation by the general practitioner.

Eligibility criteria: Inclusion Criteria:

* women aged more than 18 years old
* woman agreeing to participate to the study

Exclusion Criteria:

* women aged less than 18 years old
* woman not agreeing to participate to the study

Primary outcomes:
measure: Acceptance of gynecological consultation with a general practitioner
timeFrame: Day 0
Secondary outcomes:
measure: Women's knowledge of general practitioner gynecology competences
timeFrame: Day 0
Other outcomes:
Locations:
city: Reims
country: France
facility: Ufr Medecine Urca
Study officials:
affiliation: pratictioner
name: barbe coralie
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04375124: Treatment of Angiotensin Peptide (1-7) for COVID-19
Official title: Evaluation of the Possible Role of Angiotensin Peptide (1-7) on Treatment of COVID-19
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: COVID-19
Lead sponsor: Kanuni Sultan Suleyman Training and Research Hospital
Sponsor class: OTHER
First posted: 2020-05-05
Enrollment: 9
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: This group will receive angiotensin peptide (1-7) during their treatment at hospital.
Primary purpose: TREATMENT

Brief summary: Novel Coronavirus is reported to cause COVID-19, recently. It's known that this virus uses ACE (angiotensin converting enzyme) 2 receptors to enter human cells and also blocks the activity of ACE 2. Upon these data the investigators hypothesize that, mortal hyper-inflammation state which is shown in COVID-19 cases, can be a result of angiotensin peptide (1-7) deficiency. Therefore, the aim of this study is to evaluate the possible effect of angiotensin peptide (1-7) supplementation on treatment of COVID-19 cases.

Detailed description: Novel Coronavirus is reported to cause COVID-19, recently. It's known that this virus uses ACE (angiotensin converting enzyme) 2 receptors to enter human cells and also blocks the activity of ACE 2. Upon these data the investigators hypothesize that, mortal hyper-inflammation state which is shown in COVID-19 cases, can be a result of angiotensin peptide (1-7) deficiency. Therefore, the aim of this study is to evaluate the possible effect of plasma derived angiotensin peptide (1-7) supplementation on treatment of COVID-19 cases.

Eligibility criteria: Inclusion Criteria:

* accepted to participate with an informed consent
* proven positive COVID-19

Exclusion Criteria:

* declined to participate
* genetic/chromosomal abnormalities
* any kind of history of previous adverse events with transfusion
* diagnosis of immune deficiency

Primary outcomes:
measure: mortality
timeFrame: 4 months
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Kanuni Sultan Suleyman Training and Research Hospital
Study officials:
References:
Clinical trial NCT04917224: Study of LUNG Stereotactic Adaptive Ablative Radiotherapy
Official title: Phase II Study of LUNG Stereotactic Adaptive Ablative Radiotherapy for Central and Ultracentral Tumors
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Lung Cancer
Lung Tumor
Lead sponsor: Baptist Health South Florida
Sponsor class: OTHER
First posted: 2021-06-08
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The proposed study expands on the principles of SBRT (Stereotactic Body Radiation Therapy) and SABR (Stereotactic Ablative Radiotherapy) for centrally located NSCLC (Non-Small Cell Lung Cancer) to further optimize outcomes in this patient population with utilization of the adaptive workflow to maintain tumor control rates but decrease the incidence and grade of treatment-related toxicities.


Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years of age
* Clinical diagnosis of NSCLC
* Stage T1-2b (≤ 5 cm)

Exclusion Criteria:

* Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 1 year (i.e., carcinomas in situ of the breast, oral cavity, or cervix are permissible); previous lung cancer, if the patient is disease-free for a minimum of 1 year is permitted;
* Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
* Prior chemotherapy for the study cancer
* Plans for the patient to receive other local therapy (including standard fractionated radiotherapy and/or surgery) while on this study, except at disease progression
* Plans for the patient to receive systemic therapy (including standard chemotherapy or biologic targeted agents), while on this study, except at disease progression

Primary outcomes:
measure: Treatment completion
timeFrame: Plus or minus 5 days of treatment
measure: Number of patients experiencing adverse events
timeFrame: 12-month of treatment
Secondary outcomes:
measure: Primary Tumor Control Rate
timeFrame: 1 year of treatment
measure: Progression-free survival (PFS)
timeFrame: 1 year of treatment
measure: Overall survival (OS)
timeFrame: 1 year of treatment
measure: Functional Assessment of Cancer Therapy - Lung (FACT-L)
timeFrame: Baseline
measure: EQ-5D-5L
timeFrame: 3 and 12-month follow-up
measure: Late-Toxicity
timeFrame: 1 year of treatment
Other outcomes:
Locations:
Study officials:
affiliation: Miami Cancer Institute
name: Rupesh Kotecha, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Rosenberg SA, Mak R, Kotecha R, Loo BW Jr, Senan S. The Nordic-HILUS Trial: Ultracentral Lung Stereotactic Ablative Radiotherapy and a Narrow Therapeutic Window. J Thorac Oncol. 2021 Oct;16(10):e79-e80. doi: 10.1016/j.jtho.2021.06.030. No abstract available.
Clinical trial NCT05703724: Prevalence of Glaucoma in Belgium: a Multicenter National Trial
Official title: Prevalence of Glaucoma in Belgium: a Multicenter National Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Glaucoma
Lead sponsor: Universitaire Ziekenhuizen KU Leuven
Sponsor class: OTHER
Collaborators: name: Santen Oy
First posted: 2023-01-30
Enrollment: 1418
Sex: ALL
Minimum age (years): 40
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SCREENING

Brief summary: To screen for the presence of glaucoma in a Belgian population over 40 years old using an AI algorithm developed for the detection of glaucoma based on fundus pictures.

Detailed description: In this study, we aim to detect individuals with glaucoma and refer them for further evaluation and treatment when necessary. In so doing, we want to get an estimation of the prevalence of glaucoma in the Belgian population of 40+ years.

A fundus picture will be acquired without pupil dilation. This examination will be followed by an intra-ocular pressure measurement. The results will be discussed with the participating subject by the present physician. For each subject, both eyes will be evaluated. In case of suspected glaucoma, the subject will be referred to an ophthalmologist for further evaluation.

Eligibility criteria: Inclusion Criteria:

* Aged 40 years or above

Exclusion Criteria:

* Aged under 40 years
* Insufficient knowledge of Dutch, French or English required to complete the imaging protocol and questionnaire
* Physical or mental inability to participate

Primary outcomes:
measure: Prevalence of glaucoma in Belgium
timeFrame: 4 months
Secondary outcomes:
measure: Validation of AI algorithm
timeFrame: 7 months
Other outcomes:
Locations:
city: Edegem
country: Belgium
facility: UZA
state: Antwerpen
city: Brussel
country: Belgium
facility: Saint-Luc (UCL)
state: Brussels Hoofdstedelijk Gewest
city: Brussel
country: Belgium
facility: Hôpital Erasme
state: Brussels Hoofdstedelijk Gewest
city: Liège
country: Belgium
facility: CHU Liège
state: Luik
city: Gent
country: Belgium
facility: AZ Sint-Lucas
state: Oost-Vlaanderen
city: Leuven
country: Belgium
facility: UZ Leuven
state: Vlaams-Brabant
city: Brugge
country: Belgium
facility: AZ Sint-Jan
state: West-Vlaanderen
city: Antwerpen
country: Belgium
facility: ZNA Middelheim
Study officials:
affiliation: Universitaire Ziekenhuizen KU Leuven
name: Ingeborg Stalmans, MD, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT05003024: Comparison of Train of Four, Tetanus 50 and 100 Hz Recovery After Rocuronium Block Reversed by Sugammadex
Official title: Comparison of Train of Four, Tetanus 50 Hz and Tetanus 100 Hz Recovery Following Rocuronium Induced Neuromuscular Block Reversed by Sugamamdex
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Postoperative Residual Curarization
Lead sponsor: Poitiers University Hospital
Sponsor class: OTHER
First posted: 2021-08-12
Enrollment: 21
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Despite neuromuscular transmission monitoring and pharmacological reversal allowing a train of four ratio recovery higher than 0.9, patients receiving neuromuscular blocking agent during general anesthesia have a high risk of postoperative pulmonary complications. While this train of four ratio thershold is considered as the gold standard to confirm the lack of residual paralysis, tetanus 100 Hz stimulation showed a marked fade. This result has been observed in absence of reversal agent administration.

Therefore, the present study has been designed to compare the recovery of train of four stimulation, tetanus 50 Hz and tetanus 100 Hz stimulation in patient receiving rocuronium during general anesthesia and reversed by a specific reversal agent (sugammadex). The sugammedex will be injected once two muscular contractions of the adductor pollicis muscle will be observed after a train of four stimulation, at a dose (2mg/kg) in accordance with the clinical practice worldwide admitted.

Two questions have to be investigated. First, is this dose of sugammadex sufficient to allow a complete recovery of tetanus stimulations? Second, due to the pharmacological properties of sugammadex, does a recurarisation phenomenon occur following repeated tetanus stimulations? The attented results of this study will be to propose a new thinking on what we really need to make relevant progress in the safety aspects of residual paralysis outcome.


Eligibility criteria: Inclusion Criteria:

* ASA clinical status 1 to 3
* Informed consent obtained before anesthesia induction

Exclusion Criteria:

* ASA clinical status 4
* Emergency surgery; scheduled surgery in prone position,
* Hepatic or renal disease,
* BMI higher than 35,
* Allergy to rocuronium or sugammadex

Primary outcomes:
measure: To compare the recovery of train of four ratio with the tetanus 100 Hz ratio following sugammadex administration to reverse the rocuronium induced neuromuscular bock at the end of the surgical procedure
timeFrame: 23 minutes after sugammadex administration
Secondary outcomes:
Other outcomes:
Locations:
city: Poitiers
country: France
facility: C.H.U. de Poitiers
Study officials:
References:
Clinical trial NCT01347424: Evaluating Endostatin Plus TC Regimen in Secondary Malignant Neoplasm of Liver Using Contrast Enhancement Ultrasonography
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Non Small Cell Lung Cancer
Nasopharyngeal Cancer
Liver Metastasis
Keywords: NSCLC
NPC
Lead sponsor: Sun Yat-sen University
Sponsor class: OTHER
First posted: 2011-05-04
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Contrast enhancement ultrasonography（CEUS）could be used to evaluate the blood flow perfusion liver cancer. In this clinical trial, CEUS was used to evaluated the changes of blood flow perfusion of Secondary Malignant Neoplasm of Liver after treated with endostatin plus paclitaxel and carboplatin regimen.


Eligibility criteria: Inclusion Criteria:

* Histologic diagnosis of nasopharyngeal carcinoma or NSCLC
* With an evaluable secondary malignant neoplasm of Liver, diameter≥2cm
* Without transcatheter arterial chemoembolization (TACE) treatment
* Performance status of 0 to 1 on the Eastern Cooperative Oncology Group (ECOG) Scale.
* Estimated life expectancy of at least 3 months
* Patient compliance and geographic proximity that allow adequate follow-up.
* Adequate organ function including the following: Bone marrow: absolute neutrophil count (ANC) \>or= 1.5x10\^9/L, platelets \>or= 100x10\^9/L, hemoglobin \>or= 9g/dL. Hepatic: bilirubin \<1.5 x ULN, alkaline phosphatase, aspartate transaminase (AST) and alanine transaminase (ALT) \< 2.5 x ULN (alkaline phosphatase, AST, ALT \< 5 x ULN is acceptable if liver has tumor involvement). Renal: calculated creatinine clearance \> 45 ml/min.
* Men or women of at least 18 years of age.
* Signed informed consent from patient.

Exclusion Criteria:

* Women who are pregnant or in lactation
* Systemic treatment for another cancer within the year prior to study entry
* Known hypersensitivity to any of the study drugs or to drugs with similar chemical structures
* Use of investigational agents within 28 days of the Baseline visit, or participating simultaneously in any other clinical studies
* Severe co-morbidity of any type that may interfere with assessment of the patient for the study

Primary outcomes:
measure: The changes of blood flow perfusion in secondary malignant neoplasm of liver
timeFrame: 12months
Secondary outcomes:
measure: Comparing the difference of OS(Overall Survival) and ORR(Objective Response Rate) according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria in the two different arms.
timeFrame: 12 months
measure: Number of Participants with Adverse Events in the two different arms
timeFrame: 12 months
Other outcomes:
Locations:
city: GuangZhou
country: China
facility: SunYat-senU
state: Guangdong
Study officials:
affiliation: Cancer Center of Sun Yat-Sen University (CCSU)
name: Li Zhang
role: PRINCIPAL_INVESTIGATOR
References: